Loading...

Nyrada Inc.

NYR.AXASX
Healthcare
Biotechnology
A$0.27
A$0.00(0.00%)

Nyrada Inc. (NYR.AX) Financial Performance & Income Statement Overview

Explore the financials of Nyrada Inc. (NYR.AX), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
-14.92%
14.92%
Operating Income Growth
50.16%
50.16%
Net Income Growth
82.26%
82.26%
Operating Cash Flow Growth
89.40%
89.40%
Operating Margin
-831.02%
831.02%
Gross Margin
-127.07%
127.07%
Net Profit Margin
-499.49%
499.49%
ROE
-73.05%
73.05%
ROIC
-112.72%
112.72%

Nyrada Inc. (NYR.AX) Income Statement & Financial Overview

Access detailed annual and quarterly income data for Nyrada Inc. NYR.AX financial performance.

MetricQ2 2025Q4 2024Q2 2024Q4 2023
Revenue$797982.00$0.00$2.46M$474468.00
Cost of Revenue$1.81M$2321.00$2841.00$3204.00
Gross Profit-$1.01M-$2321.00$2.45M$471263.00
Gross Profit Ratio-$1.27$0.00$1.00$0.99
R&D Expenses$1.81M$1.14M$888654.00$4.24M
SG&A Expenses$1.55M$1.12M$1.41M$1.17M
Operating Expenses$3.36M$2.26M$2.30M$5.41M
Total Costs & Expenses$5.17M$2.26M$2.30M$5.42M
Interest Income$0.00$0.00$0.00$148817.00
Interest Expense$0.00$0.00$0.00$0.00
Depreciation & Amortization$2076.00$2321.00$2841.00$3204.00
EBITDA-$2.56M-$2.36M-$2.23M-$5.69M
EBITDA Ratio-$3.21$0.00-$0.91-$11.41
Operating Income-$4.37M-$2.26M-$2.30M-$5.42M
Operating Income Ratio-$5.48$0.00-$0.94-$11.42
Other Income/Expenses (Net)$1.11M-$107227.00$65474.00-$280374.00
Income Before Tax-$3.27M-$2.36M-$2.24M-$5.70M
Income Before Tax Ratio-$4.10$0.00-$0.91-$12.008
Income Tax Expense-$810533.00-$836344.00-$2.37M-$543036.00
Net Income-$2.46M-$1.53M$135299.00-$5.15M
Net Income Ratio-$3.08$0.00$0.06-$10.86
EPS-$0.01-$0.009$0.001-$0.03
Diluted EPS-$0.01-$0.009$0.001-$0.03
Weighted Avg Shares Outstanding$190.50M$162.36M$156.009M$156.009M
Weighted Avg Shares Outstanding (Diluted)$190.50M$162.36M$170.45M$156.009M

Over the last four quarters, Nyrada Inc. achieved steady financial progress, growing revenue from $474468.00 in Q4 2023 to $797982.00 in Q2 2025. Gross profit stayed firm with margins at -127% in Q2 2025 versus 99% in Q4 2023. Operating income totaled -$4.37M in Q2 2025, maintaining a -548% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$2.56M. Net income dropped to -$2.46M, with EPS at -$0.01. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;